Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NSD2 | O96028 | 1/20 | 0.60 |
| ▸ | ACLY | P53396 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.55 |
| ▸ | MAPT | P10636 | 3/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | BLM | P54132 | 1/20 | 0.55 |
| ▸ | AGER | Q15109 | 1/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | KDM4A | O75164 | 2/20 | 0.54 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.54 |
| ▸ | KDM6B | O15054 | 1/20 | 0.54 |
| ▸ | KDM6A | O15550 | 1/20 | 0.54 |
| ▸ | TET3 | O43151 | 1/20 | 0.54 |
| ▸ | KDM4B | O94953 | 1/20 | 0.54 |
| ▸ | KDM5C | P41229 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL335469 | 1.00 | NSD2 (0.60) | NSD2ACLYKDM4ETDP1L3MBTL1 | |
| SCHEMBL28727190 | 0.98 | NSD2 (0.59) | NSD2ACLYKDM4ETDP1L3MBTL1 | |
| SCHEMBL5680479 | 0.98 | NSD2 (0.59) | NSD2ACLYKDM4ETDP1L3MBTL1 | |
| Hydrochloric Acid SCHEMBL5450942 | 0.98 | NSD2 (0.59) | NSD2ACLYKDM4ETDP1L3MBTL1 | |
| SCHEMBL5680469 | 0.98 | NSD2 (0.59) | NSD2ACLYKDM4ETDP1L3MBTL1 | |
| Formaldehyde SCHEMBL27690889 | 0.96 | NSD2 (0.57) | NSD2ACLYKDM4ETDP1L3MBTL1 | |
| Acetic Acid SCHEMBL27656229 | 0.95 | NSD2 (0.56) | NSD2ACLYKDM4ETDP1L3MBTL1 | |
| Aziridine SCHEMBL27648195 | 0.92 | NSD2 (0.54) | NSD2ACLYKDM4ETDP1L3MBTL1 | |
| Alcohol SCHEMBL28316967 | 0.92 | NSD2 (0.57) | NSD2ACLYKDM4ETDP1L3MBTL1 | |
| Quinoline SCHEMBL27803388 | 0.92 | NR4A1 (0.58) | NSD2ACLYKDM4ETDP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119556538-A | Alkaline stripping liquid for silicon-based surface composite film and stripping method thereof | 湖北兴福电子材料股份有限公司 | 2025-03-04 | — | — | CN | claimed |
| EP-4340989-A1 | METHOD OF MANUFACTURE AND SCALE-UP OF THE METAL-ORGANIC FRAMEWORK CU(QC)2 | ExxonMobil Technology and Engineering Company (US) | 2024-03-27 | — | — | EP | claimed |
| WO-2022246150-A1 | METHOD OF MANUFACTURE AND SCALE-UP OF THE METAL-ORGANIC FRAMEWORK CU(QC)2 | ExxonMobil Technology and Engineering Company (US) | 2022-11-24 | — | — | WO | claimed |
| CN-119661553-A | Brucea javanica kurol quinoline derivative and preparation method and application thereof | 中国人民解放军西部战区总医院 | 2025-03-21 | — | — | CN | disclosed |
| CN-119556538-A | Alkaline stripping liquid for silicon-based surface composite film and stripping method thereof | 湖北兴福电子材料股份有限公司 | 2025-03-04 | — | — | CN | disclosed |
| EP-4340989-A1 | METHOD OF MANUFACTURE AND SCALE-UP OF THE METAL-ORGANIC FRAMEWORK CU(QC)2 | ExxonMobil Technology and Engineering Company (US) | 2024-03-27 | — | — | EP | disclosed |
| WO-2024026423-A1 | SUBSTITUTED QUINOLINE DERIVATIVES AS PI3K INHIBITORS | BLACK DIAMOND THERAPEUTICS, INC. (US) | 2024-02-01 | — | — | WO | disclosed |
| US-20230203058-A1 | MACROCYCLIC DIAMINE DERIVATIVES AS ENT INHIBITORS FOR THE TREATMENT OF CANCERS, AND COMBINATION THEREOF WITH ADENOSINE RECEPTOR ANTAGONISTS | iTeos Belgium SA (BE) | 2023-06-29 | — | — | US | disclosed |
| EP-4097101-A1 | 1H-PYRAZOLO[4,3-D]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS | Bristol-Myers Squibb Company (US) | 2022-12-07 | — | — | EP | disclosed |
| WO-2022246150-A1 | METHOD OF MANUFACTURE AND SCALE-UP OF THE METAL-ORGANIC FRAMEWORK CU(QC)2 | ExxonMobil Technology and Engineering Company (US) | 2022-11-24 | — | — | WO | disclosed |
| EP-4055014-A1 | PYRROLIDINE AND PIPERIDINE COMPOUNDS | Yuhan Corporation (KR) | 2022-09-14 | — | — | EP | disclosed |
| EP-4021406-A1 | COMPOSITIONS FOR SMALL MOLECULE THERAPEUTIC AGENT COMPOUNDS | Delpor, Inc. (US) | 2022-07-06 | — | — | EP | disclosed |
| WO-2022063303-A1 | A CLASS OF FUSED RING COMPOUNDS, AND PREPARATION AND USE THEREOF | 石药集团中奇制药技术（石家庄）有限公司 | 2022-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203058-A1 | MACROCYCLIC DIAMINE DERIVATIVES AS ENT INHIBITORS FOR THE TREATMENT OF CANCERS, AND COMBINATION THEREOF WITH ADENOSINE RECEPTOR ANTAGONISTS | ENTPD1, SLC29A1, ENTPD5 | NSD2 2023/4885ACLY 1505/4885KDM4E 2852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.